MarginsXMarginsX
Home › Markets › Health Care › DARE

Dare Bioscience Inc. (DARE)

DARE trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$0.5842
-11.13% on the day
Market cap
$11.5M
Nano cap
Revenue · 2025
$1.0M
+10429.4% on 2024
Net income · 2025
-$13.4M
-1300.7% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1401914/000140191426000004/0001401914-26-000004-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerDARE on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2014
SEC CIK0001401914
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$1.0M
Net income-$13.4M
Operating income-$13.6M
Net margin-1300.7%
Operating margin-1315.5%
Revenue growth+10429.4%
Cash$24.7M
Total assets$32.5M
P/E (computed)Net income was not positive
P/S (computed)11.2×

Warning signs

Cash runway
13.4 months
$12.6M cash at June 30, 2026
Share count, 1 year
+13.4%
2025-08-13 to 2026-08-12 · +109.0% over 3 years
Going-concern doubt
Yes
10-Q filed August 13, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"Based on the Company's current analysis of the conditions described above, there is substantial doubt about the Company's ability to continue as a going concern 7 within the 12 month period from the issuance date of the accompanying condensed consolidated financial statements given that the timing and amount of potential revenue the Company may generate remain uncertain."
10-Q 2026-08-13
Cash and burn$12.6M cash; operating cash flow -$2.8M a quarter.Report 2026-06-30
Shares outstanding15,289,502 (2026-08-12); 13,479,502 a year earlier; 87,785,166 three years earlier. 3y figure adjusted for splits (1-for-12 overall).Cover page 2026-08-12
Reverse splits, 3 years1; latest 1-for-12 on 2024-07-01Source 2024-07-01
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the marketLatest 2026-08-17
Exchange deficiency notices, 12 months2 (8-K item 3.01)8-K 2026-10-02
AuditorHaskell & White LLP, Irvine, California, United StatesPCAOB Form AP 2026-03-26
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q2 2026
2026-06-30
$188K-$3.0M-$6.8M$12.6MNo debt tags$1.4M10-Q 2026-08-13
Q1 2026
2026-03-31
$152K-$3.0M-$5.5M$18.5MNo debt tags$1.2M10-Q 2026-05-14
Q4 2025
2025-12-31
$1.0M-$1.4M$1.4M$24.7MNo debt tags$1.0M10-K 2026-03-26
Q3 2025
2025-09-30
$2K-$3.6M-$442K$23.1M$11K-$57K10-Q 2025-11-13
Q2 2025
2025-06-30
-$21K-$4.0M-$5.4M$5.0M$188K-$18K10-Q 2026-08-13
Q1 2025
2025-03-31
$25K-$4.4M-$5.5M$10.3M$92K$26K10-Q 2026-05-14
Q4 2024
2024-12-31
-$64K-$5.5M$5.3M$15.7M$4K$10K10-K 2026-03-26
Q3 2024
2024-09-30
$42K-$4.7M-$5.9M$11.2MNo debt tags$1.9M10-Q 2024-11-14

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B32026-09-04
Latest annual report10-K2026-03-26
Latest quarterly / interim10-Q2026-11-16
Latest current report8-K2026-11-16
Latest proxyDEFA14A2026-10-27

Source: SEC EDGAR submissions feed, 781 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+2.8%
1 month-12.2%
3 months-52.0%
Year to date-66.0%
1 year-65.2%
From 52-week high-79.9%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
BIVIBioVie Inc.$1.08-4.42%$11.6M
ASBPAspire-Lakewood Holdings Inc.$8.06-5.29%$11.3M
LSTALisata Therapeutics Inc.$1.09-9.92%$11.8M
RADXRadiopharm Theranostics Limited$0.7676+1.00%$11.1M
PTNPalatin Technologies Inc.$6.13-1.69%$10.9M
QNTMQuantum Biopharma Ltd. Class B Subordinate Voting Shares$1.44-10.56%$12.2M
HINDVyome Holdings Inc.$1.53-3.16%$10.7M
OPTHOptimi Health Corp. Common Shares$2.15-4.44%$12.3M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier